VALEANT PHARMACEUTICALS INTERNATIONAL, INC., n/k/a BAUSCH HEALTH COMPANIES INC. | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for VALEANT PHARMACEUTICALS INTERNATIONAL, INC., n/k/a BAUSCH HEALTH COMPANIES INC.

Sort by

Viewing results 1‒25 of 48

Bausch & Lomb Inc
Bausch & Lomb climbs in debut after downsized listing
...Bausch & Lomb, the eyecare unit of the company formerly known as Valeant Pharmaceuticals, had been aiming to raise up to $840mn, on Thursday evening but eventually sold at $18 per share, raising $630mn....
May 6, 2022
LexBausch & Lomb Inc
Bausch & Lomb: eyecare IPO does not signal thaw in new listing market Premium content
...Worse, Bausch Health — formerly known as Valeant Pharmaceuticals — paid $2.4bn more for it back in 2013....
May 6, 2022
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
FT Magazine
Inside the secret, often bizarre world that decides what porn you see
...And I take my bra off or pull the cups down and I jiggle my shoulders while saying, ‘T-h-a-n-k-y-o-u,’” she says, making her voice go jittery and giving a brief shimmy. “It’s very cute....
June 24, 2022
Pharmaceuticals sector
Bausch Health spins off eye-care business
...The company formerly known as Valeant — which two years ago rebranded itself as Bausch Health after a string of scandals over pricing and accounting irregularities — is spinning off its eye-care business...
August 6, 2020
Due Diligence
IPOs postponed and debt offerings shelved. Coronavirus-induced volatility is gumming up critical sources of capital Premium content
...Record label Warner Music and shoe maker Cole Haan have both delayed IPOs; Micro Focus, one of Britain’s largest listed technology businesses, shelved a $1.4bn loan on Monday; and Bausch Health has put its...
March 4, 2020
Pharmaceuticals sector
Valeant to return ‘female Viagra’ maker to former owners
...When Valeant acquired Sprout Pharmaceuticals in August 2015, analysts and investors said the Canadian drugmaker had vastly overpaid for the first medicine designed to boost a woman’s libido....
November 6, 2017
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
Fund management
Ackman’s exit from Valeant piles pressure on Paulson
...Bill Ackman’s exit from Valeant Pharmaceuticals has dealt a blow to another high-profile hedge fund manager, John Paulson, who is sitting on his own $2bn-plus loss on the healthcare stock....
March 15, 2017
Pharmaceuticals sector
FT Health: Research pledge must go further
...news www.ft.com/health and @FT_Health ———- Final thought The WannaCry hack attack is a stark reminder that governments and companies alike must not skimp on resources for the systems that keep us safe...
May 19, 2017
Pharmaceuticals sector
Allergan to pay $15m over merger disclosures
...The settled order relates to disclosures made by Allergan, Inc. in SEC filings in 2014, during the pendency of the tender offer by Valeant Pharmaceuticals International for the common stock of Allergan,...
January 17, 2017
Pharmaceuticals sector
Chinese conglomerate buys cancer drug maker from Valeant Pharma
...Canadian drugmaker Valeant Pharmaceuticals International Inc said Tuesday it will sell controversial prostate-cancer drug maker Dendron Pharmaceuticals to Chinese conglomerate Sanpower Group Co – which also...
January 10, 2017
News in-depthWeek in Review
Week in Review, December 3
...Allergan, a rival drugmaker that had been touted by analysts as a potential buyer for Salix and Bausch & Lomb, Valeant’s contact lens business, said it was not interested in acquiring either....
December 2, 2016
News in-depthThe Big Read
Pharmaceuticals: Staying power
...It was October of last year and the pharmaceuticals industry was firefighting an explosion set off by Martin Shkreli, the enfant terrible of drug making, who sparked an international outcry by raising the...
August 21, 2016
FT AlphavilleEquities
A Valeant reminder
...You could pin this on the pre-release snafu… /C O R R E C T I O N — Valeant Pharmaceuticals International, Inc./ March 15, 2016 In the news release, Valeant Pharmaceuticals Reports Preliminary Unaudited...
March 15, 2016
US & Canadian companies
Mylan to launch cut-price generic version of EpiPen
...Valeant, the Canadian drugmaker, has also been targeted by Mrs Clinton, as has Martin Shkreli, who became an international pariah after increasing the price of a medicine given to Aids sufferers from $13.50...
August 29, 2016
US & Canadian companies
Big pharma thinks twice about jacking up drug prices
...The change of heart follows a public outcry over the case of Martin Shkreli and his company Turing Pharmaceuticals, which acquired the rights to Daraprim, a drug often given to cancer and Aids patients,...
October 8, 2015
FT Live
Global Private Banking Awards 2024
Celebrating excellence in wealth management
Thursday, 7 NovemberThe Landmark London, London, UK
US & Canadian companies
Week in Review, January 9
...However, this only reflects activity at the hedge fund’s UK division, meaning total pay across all of its international business is likely to be higher....
January 8, 2016
US & Canadian companies
Valeant buys maker of ‘female Viagra’ for $1bn
...health watchdog....
August 20, 2015
High yield bonds
Healthcare junk bonds sting investors
...Prices of bonds issued by a number of the companies that have been accused of overpricing — including Valeant Pharmaceuticals, Endo International and Mallinckrodt — have fallen sharply, pushing up yields...
October 1, 2015
High yield bonds
Music shifts for credit investors in 2015
...Fears surrounding Valeant reverberated through to other junk-rated healthcare companies, including Endo International and Mallinckrodt....
December 30, 2015
The Monday Interview
The Botox initiation of Brent Saunders, Actavis chief executive
...His appointment in 2010 as CEO of Bausch & Lomb, an eyecare company, kicked off five years of frenetic dealmaking, starting with the sale of the contact lens maker to Valeant, a drug company, before moving...
May 17, 2015
When Rates Rise
Interest rate rise: turning point looms for US debt binge
...Analysts say the pharmaceuticals and healthcare industry, which has been engaged in a wave of debt-fuelled dealmaking, could be one of the hardest hit sectors when rates rise....
September 9, 2015
US & Canadian companies
Allergan aims to keep beauty lead as needle replaces the knife
...and health systems will generally find a way of paying for it....
June 21, 2015
US & Canadian companies
Endo to buy Par from TPG Capital in $8bn cash-and-shares deal
...The deal is the latest in a feverish game of brinkmanship being played out by some of the biggest companies in the pharmaceuticals sector....
May 18, 2015
US & Canadian companies
Hungry Actavis pauses to digest Allergan
...Less than two years ago, he was chief executive of Bausch & Lomb, a company he sold, as chance would have it, to Valeant for $8.7bn....
January 21, 2015
US & Canadian companies
Allergan-Actavis deal follows battle for soul of pharma
...eyecare group Bausch & Lomb....
November 17, 2014

Previous pagePage 1 of 2Next page